Melior Discovery Announces IND Approval for Novel Diabetes Drug MLR1023

EXTON, Pa, March 16, 2009 (PRNEWSWIRE) – Melior Discovery, Inc. today announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of its novel first-in-class kinase activator, MLR-1023, for the treatment of Type II diabetes. MLR-1023 was discovered and developed internally using Melior’s indications discovery platform, theraTRACE®.

“We are delighted to have been given the go-ahead by the FDA to advance MLR-1023 into clinical development,” said Dr Andrew Reaume, President and Chief Executive Officer of Melior. This IND, represents a major milestone for Melior Discovery, and underscores the productivity of our theraTRACE® indications discovery engine. In addition to MLR-1023, we have a number of other programs also progressing towards the clinic.”

“Pre-clinical studies suggest that MLR-1023 has the potential to be developed as an effective drug treatment for Type II diabetes both alone and in combination with available therapies,” added Dr Reaume.

About Diabetes

More than 150 million people worldwide have diabetes, with approximately 90% suffering from Type II diabetes. An estimated 16 million people in the United States suffer from Type II diabetes, which is often part of a metabolic syndrome that includes obesity, elevated blood pressure and high levels of blood lipids. About 80% of people with Type II diabetes mellitus are overweight.

Melior Discovery Overview

Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE® platform of multiplexed in vivo models. The Company is building a pipeline of drug candidates by identifying “privileged” compounds that have been discontinued by other companies and repositioning these molecules in new high potential therapeutic areas. Melior is fortunate to be working exclusively with Dr. Chris Lipinski who assists the Company in identifying ideal repositioning candidates. In addition, Melior offers pharmaceutical and biotechnology companies an opportunity to expand their development pipelines by accessing the theraTRACE® platform.

Melior Discovery is located in Exton, PA. For more information contact:

Andrew Reaume, Ph.D MBA
President and CEO
Melior Discovery
860 Springdale Drive
Exton, PA 19341

(+1) 610-280-0633 ext 239

e-mail: areaume@meliordiscovery.com